LeMaitre Vascular (LMAT) Stock Price, News & Analysis

Company Overview

LeMaitre Vascular, Inc. is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D. LeMaitre, a vascular surgeon who sought to improve patient outcomes through innovation, the company has introduced numerous technologies that have become standards in surgical practice. Early success with devices such as the LeMaitre valvulotome laid the groundwork for ongoing expansion into complementary product categories. Over the decades, the company has grown both organically and through targeted acquisitions, continuously enhancing its ability to deliver comprehensive solutions for blood flow restoration.

LeMaitre Vascular sells its products worldwide, with direct sales and distribution partnerships spanning North America, Europe, Asia-Pacific and Latin America. Its international footprint allows it to collaborate with hospitals, surgical centers and healthcare systems around the globe, adapting its technology portfolio to meet regional regulatory requirements and clinical preferences. By maintaining a network of field-based clinical specialists and customer support teams, the company ensures that its innovations are effectively integrated into surgical workflows.

Committed to ongoing research and development, LeMaitre Vascular invests in advancing technologies that address unmet clinical needs in vascular surgery. The company’s leadership team brings together expertise in medical device engineering, regulatory affairs and commercial strategy, guiding efforts to expand into new markets and therapeutic areas. Through its focus on quality, innovation and customer partnership, LeMaitre Vascular aims to improve long-term patient outcomes in the treatment of peripheral vascular disease.

Key Stats

• Today's Range: $91.07 to $93.35
• 50-Day Range: $91.42 to $117.39
• 52-Week Range: $79.00 to $118.01
• Volume: 212,383 shs
• Average Volume: 296,048 shs
• Market Capitalization: $2.10 billion
• P/E Ratio: 33.93
• Dividend Yield: 1.09%
• Price Target: $112.60
• Consensus Rating: Moderate Buy

LeMaitre Vascular Stock Analysis - MarketRank™

LeMaitre Vascular scored higher than 97% of companies evaluated by MarketBeat, and ranked 25th out of 862 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

LeMaitre Vascular has a consensus price target of $112.60, representing about 22.4% upside from its current price of $91.96.

Amount of Analyst Coverage

LeMaitre Vascular has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 9.00%

Earnings Growth

Earnings for LeMaitre Vascular are expected to grow by 9.00% in the coming year, from $3.00 to $3.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LeMaitre Vascular is 33.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of LeMaitre Vascular is 33.93, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.24.

Price to Earnings Growth Ratio

LeMaitre Vascular has a PEG Ratio of 2.55. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

LeMaitre Vascular has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.61% of the float of LeMaitre Vascular has been sold short.

Short Interest Ratio / Days to Cover

LeMaitre Vascular has a short interest ratio ("days to cover") of 3.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LeMaitre Vascular has recently increased by 3.00%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

LeMaitre Vascular pays a meaningful dividend of 1.09%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

LeMaitre Vascular has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of LeMaitre Vascular is 36.90%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 30.58% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.33

News Sentiment

LeMaitre Vascular has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for LeMaitre Vascular this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for LMAT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,906,174.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of LeMaitre Vascular is held by insiders.

Percentage Held by Institutions

84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/26 Dividend: 3/12/2026
• Ex-Dividend for 3/26 Dividend: 3/12/2026
• Dividend Payable: 3/26/2026
• Last Earnings: 5/05/2026
• Record date for 6/4 Dividend: 5/21/2026
• Ex-Dividend for 6/4 Dividend: 5/21/2026
• Dividend Payable: 6/04/2026
• Today: 6/14/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LMAT
• CIK: 1158895
• Web: www.lemaitre.com
• Phone: (781) 221-2266
• Fax: 781-425-5049
• Employees: 490
• Year Founded: 1983

Price Target and Rating

• Average Price Target for LeMaitre Vascular: $112.60
• High Price Target: $127.00
• Low Price Target: $95.00
• Potential Upside/Downside: +22.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.71
• Trailing P/E Ratio: 33.93
• Forward P/E Ratio: 30.65
• P/E Growth: 2.55
• Net Income: $57.73 million
• Net Margins: 24.35%
• Pretax Margin: 31.46%
• Return on Equity: 15.36%
• Return on Assets: 9.78%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 14.32
• Quick Ratio: 12.20

Sales & Book Value

• Annual Sales: $249.60 million
• Price / Sales: 8.42
• Cash Flow: $2.90 per share
• Price / Cash Flow: 31.69
• Book Value: $17.35 per share
• Price / Book: 5.30

Miscellaneous

• Outstanding Shares: 22,850,000
• Free Float: 21,160,000
• Market Cap: $2.10 billion
• Optionable: Optionable
• Beta: 0.54